🔴 We are now live with an insightful presentation by Dr. Sven Borchmann, MD, PhD, Principal Investigator at the University of Cologne and Founder & Managing Director of Liqomics, Germany, discussing how liquid biopsy innovations are being translated into routine patient care across Europe.
Presentation: Bringing Liquid Biopsy Tests to Patients: A European Perspective
While liquid biopsy technologies continue to advance at an unprecedented pace, translating these innovations from the research laboratory into everyday clinical practice remains a significant challenge. In this session, Dr. Borchmann is sharing a comprehensive European perspective on how scientific discoveries become clinically validated, regulatory-approved, and widely accessible diagnostic solutions.
Drawing on his experience as both a physician-scientist and entrepreneur, Dr. Borchmann explores the critical steps involved in implementing liquid biopsy within healthcare systems, including clinical validation, regulatory approval, reimbursement strategies, quality assurance, and integration into routine oncology practice.
The presentation also highlights the importance of collaboration between academia, healthcare providers, industry, and policymakers in accelerating the adoption of liquid biopsy technologies, ensuring that innovative diagnostic tools reach patients more efficiently and improve outcomes across multiple cancer types.
This engaging session provides valuable insights into the future of precision oncology and demonstrates how Europe is helping shape the next generation of clinically accessible liquid biopsy solutions.
We extend our sincere thanks to Dr. Sven Borchmann for sharing his expertise and to our global audience for joining us in today’s scientific discussions.
This conference is organized by Impact Research Communications (IRC)
More info: https://liquidbio.ircconferences.net/ | Advances in Liquid Biopsy
